🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Valneva SE (EPA:VLA)
France flag France · Delayed Price · Currency is EUR
2.363
-0.087 (-3.55%)
Nov 20, 2026, 5:37 PM CET
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

Lyme discussions with the FDA are extending the BLA timeline, while European approval and a fall 2027 launch remain targeted. Shigella showed encouraging challenge-model and immune-response data, but further optimization awaits greater Lyme and funding clarity.

Maury Raycroft
Analyst, Jefferies

Analyst at Jefferies. I would like to welcome the CEO of Valneva, Thomas Lingelbach, who is joining us today. We are going to do a fireside chat format. Maybe for those who are new to the Valneva story, if you can give a one-minute intro to the company.

Thomas Lingelbach
CEO, Valneva

Thank you so much, Maury. Valneva is a unique vaccine company with a proven track record in bringing vaccines from bench to licensure. We have done that successfully three times in our history, and hopefully number four with Lyme disease will come soon, which is certainly the most important catalyst for the company. We are fully integrated. We do everything from research to sales with a commercial business that is cash generative and a pipeline of very interesting new R&D assets.

Maury Raycroft
Analyst, Jefferies

Great. It is a nice intro. For the Lyme disease program, let us spend some time on that. It is partnered with Pfizer. Earlier this year, the phase III showed 73.2% efficacy, but narrowly missed the primary analysis pre-specified confidence interval threshold. A second pre-specified analysis, which included one additional placebo case, cleared that threshold. Pfizer has since been discussing the path to BLA submission with FDA. Just to start off, can you frame where those discussions stand today and what remains to be resolved?

Thomas Lingelbach
CEO, Valneva

So you are absolutely right. On the efficacy, we had a pinpoint landing in the study. We conducted many different animal models and animal studies beforehand. We were predicting around 75% efficacy, and we landed there. So clinically, highly meaningful. We also experienced an excellent safety profile, which Pfizer presented two weeks ago at IDWeek, which is really as clean as it can be. But a statistical miss on the lower bound of the confidence interval. Now, when you are in such a situation, you need to clear with regulatory agencies how you could still ensure licensure on the back of this single clinical study by adopting additional contributing models and factors that, in totality, will provide you sufficient clinical evidence for licensure. This process is being led by Pfizer, who own this program, and our co-development phase got concluded with the end of the phase III study.

The clearance process with the European Medicines Agency has been concluded, and the file got submitted and accepted by the European Medicines Agency, got, in the meantime, also submitted with Health Canada. The missing part is FDA and BLA. On that process, there are many discussions still ongoing. All in all, applying the approach of the totality of clinical evidence, as presented by Pfizer at IDWeek, it includes also a so-called correlate of risk approach. This means, as a contributing factor, you also bridge your immunogenicity data against the Lyme cases, both the symptomatic as well as the asymptomatic Lyme cases. You show that when people reach a certain immunological threshold, the risk of experiencing Lyme disease is being substantially decreased.

This, in combination with the review of the Lyme cases over time, following different vaccinations, including a booster, is supposed to be the decisive package, or let's say, the package that is intended to support licensure. This will also be coupled with, of course, risk-benefit and health economical benefit analysis, and the alignment of the post-marketing effectiveness surveillance or post-marketing studies in general. This has taken or is taking a bit longer with the FDA, and I'm not going to comment why and how, but we are optimistic and confident that with our partner, who are really doing an excellent work here, we will see also a pathway into the United States, which is representing approximately 50% of the anticipated commercial opportunity. The rest will be Europe and ex-U.S.

Maury Raycroft
Analyst, Jefferies

Got it. Okay. I think that's a good overview on where you're at with this. One of the questions we had is just with Pfizer leading the FDA discussions, what's the cadence of regulatory updates that you're getting, and how much visibility do you have into the remaining steps before the BLA submission and acceptance?

Thomas Lingelbach
CEO, Valneva

Yeah, it's a good question, Maury. First of all, it's fair to say that our partnership with Pfizer are almost like two different agreements under one roof. We had a period of co-development. This period of co-development was really a period where we shared not only financial resources, 40/60, but also people, capabilities, expertise. Then the second part, where Pfizer has full control over the licensure process, future manufacturing, and global commercialization. We are now in the second phase of this collaboration, so we are getting secondhand information through Pfizer. So, we are not having a seat on the table anymore in all the respective regulatory discussions, and therefore, there's also, unfortunately, only a limited amount of information that we are allowed to share.

Maury Raycroft
Analyst, Jefferies

Makes sense. I guess you've discussed Pfizer working with FDA on a revised statistical analysis incorporating symptomatic cases, seropositive infections, immunogenicity, the correlate of risk approach, you talked about this. How much of that additional work was specifically requested by FDA versus proactively put together by Pfizer?

Thomas Lingelbach
CEO, Valneva

From my perspective, most of it is work that you would have done with any regulatory authority in a situation like the one that we have experienced. I'm anticipating that the FDA had probably here and there slightly different requests, but I do not want to speculate too much about that.

Maury Raycroft
Analyst, Jefferies

Okay. We were previously expecting a potential BLA acceptance announcement by Pfizer by the end of this year, but that now appears to have shifted into early 2027. What's driving the longer timeline there?

Thomas Lingelbach
CEO, Valneva

As I said, it's ongoing regulatory discussions, A, on the final data package in support of licensure, but also any or all conversations associated with post-marketing requirements. This is a major difference in between other regulatory bodies and the FDA, because FDA expect those things to be cleared by the time you submit the BLA. With other regulatory authorities, you are also able to do this in parallel. This is certainly driving the timeline, I am personally convinced that Pfizer do not want to risk a refusal to file, therefore, the more you align upfront, the better it is.

Maury Raycroft
Analyst, Jefferies

Yeah.

Thomas Lingelbach
CEO, Valneva

This is driving the timeline. We hope, of course, that a submission will still take place this side of Christmas, because otherwise, the later it comes, the higher the risk that one may lose a full commercial year, because also the program is fast-tracked. There is a certain timeline that an anticipated licensure process will take, and if you cannot launch in fall in any given year, you are going to lose a

Maury Raycroft
Analyst, Jefferies

Right

Thomas Lingelbach
CEO, Valneva

complete commercial year due to the seasonality of Lyme disease. This is where we are right now.

Maury Raycroft
Analyst, Jefferies

You do have motivation to launch before fall of 2027. That is the goal. You mentioned the surveillance studies and potential post-marketing commitments. How much insight do you have into FDA's expectations there, and what are you anticipating in terms of what those commitments could look like? Could FDA request another study, for example?

Thomas Lingelbach
CEO, Valneva

We are not anticipating that FDA will ask for an additional study. On the other phase IV activities, we have good visibility, but unfortunately cannot talk about it at this point in time.

Maury Raycroft
Analyst, Jefferies

Okay. Under the current agreement, Pfizer is responsible for funding post-marketing commitments. If FDA requirements are viewed as extensive, could that lead to some sort of an amendment with that agreement?

Thomas Lingelbach
CEO, Valneva

Valneva's view at this point in time is very clear. We have a contract. The contract is absolutely crystal clear at this point in time when it comes to activities needed through licensure and post-licensure. We have paid our part, and all deal terms are connected to this existing agreement, which we continue to believe is not only a great partnership with Pfizer, but also a commercially attractive agreement for Valneva, which doesn't mean that a company like Pfizer won't come back and renegotiate at a certain point in time, but we are not anticipating that.

Maury Raycroft
Analyst, Jefferies

Got it. Okay. Are you expecting a VRBPAC advisory committee meeting as the base case? With the primary endpoint miss, how confident are you that the totality of the data would lead to a favorable outcome there?

Thomas Lingelbach
CEO, Valneva

Personally, I am very confident, and I repeat also what the Pfizer management has repeatedly communicated, namely their degree of confidence. When it comes to VRBPAC, Valneva's assumption is that there will be a VRBPAC.

Maury Raycroft
Analyst, Jefferies

Got it. Okay. Assuming FDA accepts the BLA following extensive discussions with Pfizer, would you view VRBPAC as a meaningful approval hurdle to overcome, or would you expect its recommendations to focus more on labeling and post-marketing requirements?

Thomas Lingelbach
CEO, Valneva

Oh, that's a good question, Maury. I would say I've personally gone through many, many VRBPACs in my life. Everyone is probably slightly different. But I believe that the main focus is going to be on risk-benefit, and health economical benefit, reviewing the totality of evidence, and that I believe will be the key focus of this VRBPAC.

Maury Raycroft
Analyst, Jefferies

And you'd be confident on going into that meeting with the data now?

Thomas Lingelbach
CEO, Valneva

I see no reason why one should not go positively into such a meeting, given the huge unmet medical need around Lyme disease, given the fact that we are many, many years away from any other potential prophylactic or even therapeutic solution. Therefore, yes, very confident.

Maury Raycroft
Analyst, Jefferies

Got it. Okay. FLUAD QUADRIVALENT received accelerated approval based on immunogenicity, despite failing to meet the pre-specified lower bound of the 95% confidence interval for efficacy, with confirmatory efficacy studies required post-approval. How relevant is this example to VLA15, and do you have more perspective on key similarities and differences?

Thomas Lingelbach
CEO, Valneva

Yeah. You are making a couple of good remarks here. I mean, it is a question that we are receiving all the time. Is there precedence in the vaccine world? Which vaccines got a license on the back of what? I mean, the reality is, and I am doing vaccine development now for more than 30 years, every single development is different. You need to review every single situation specifically. But yes, there are multiple pathways how you can get a license despite of a miss on the first pre-specified analysis. As I said, I mean, we are confident that there will be a positive outcome. We share the optimism that Pfizer have expressed now at multiple occasions. We have no other choice but to wait for things to unfold and get us to the additional level of certainty that we need also for the capital market.

Maury Raycroft
Analyst, Jefferies

Yeah. Makes sense. How might accelerated approval versus traditional approval influence ACIP recommendations, payer coverage, and commercial uptake?

Thomas Lingelbach
CEO, Valneva

That's unfortunately another question where I can only say it depends. I mean, there have been accelerated approval pathways where recommendations were affected. There are others where they were not affected. We are not currently assuming that we will apply here an accelerated approval pathway, and therefore it will be a more the so-called novel approach, namely a single study supporting licensure. The guidance document is called novel approach, and that in combination with additional clinical evidence.

Maury Raycroft
Analyst, Jefferies

Makes sense. You mentioned Pfizer's further along with EMA versus FDA with licensure. We're estimating that you get the Day 120 list of questions potentially around December. Have you already got those questions yet, or does that timeline make sense? What are your expectations for this milestone, and will you do some sort of a public update around that?

Thomas Lingelbach
CEO, Valneva

First of all, of course, the EMA process is extremely transparent. You know that there is a timetable associated with each and every submission. Yes, of course, according to this timetable, one could expect the Day 120 list of questions literally very, very soon. I mean, what will the Day 120 list of questions tell any company submitting an MAA? It will accumulate a list of issues, questions, additional information requests, and I would say the overall amount of asks will determine the length of the clock stop, because the clock will stop, and then the company has time to submit all this information, respond to additional questions, and then the clock will start again. So the material part will be when the clock starts again.

I mean, it will be made public through CHMP minutes that the Day 120 list of questions has been submitted, and then at a certain point in time, one will know when the clock will start again. That will determine the final timeline to licensure, which we still expect, as we originally said, by the way, in the fall of 2027. That would be ideal that the product could be launched in the fall of 2027 in key European countries. Of course, Pfizer have a huge commercial machinery, including specialization in tick-transmitted diseases with their TBE franchise in Europe. So we believe that they will be ready to give it a jumpstart.

Maury Raycroft
Analyst, Jefferies

Got it. Would they be ready to launch in some regions then in the fall of next year?

Thomas Lingelbach
CEO, Valneva

We have not discussed launch planning in detail, but this is our current hypothesis, yes.

Maury Raycroft
Analyst, Jefferies

Okay. You mentioned IDWeek, which just recently happened in October. You mentioned some of the safety data and incremental efficacy that was disclosed there too. Is that being leveraged in the FDA conversations? Also, when could we expect more analyses, including the first season efficacy and regional results?

Thomas Lingelbach
CEO, Valneva

Yes. First of all, yes, of course. Nothing will be presented at a conference that has not been submitted in a submission process. That would be foolish to do. Yes, of course, as soon as the data packages have been fully submitted, we are anticipating that more details will be shared, because this has been a very complex study with many, many interesting data. Of course, the vast majority of the detailed data can only and will only be made public once it has been received by the respective regulatory agencies.

Maury Raycroft
Analyst, Jefferies

Makes sense. You mentioned the hypothesis is that you would be able to launch in Europe in the fall. You have also said that it could be a nine to 12-month process for getting reimbursement in some of the countries in the E.U. How should investors think about the pace of commercial uptake across the region?

Thomas Lingelbach
CEO, Valneva

Oh, that is a very good question. You talked earlier about examples in the vaccine space. Many, many novel vaccines had an initial commercial period prior to vaccine recommendations to be adopted. Different companies call it differently, but we expect definitely that there will be an initial period short of final recommendations, because those will take a while. You have this early launch phase, which got adopted by also recently with new vaccine introductions quite comprehensively.

Maury Raycroft
Analyst, Jefferies

Got it. Okay. Let us talk about Shigella too, where you just had an update last week.

Thomas Lingelbach
CEO, Valneva

Yeah

Maury Raycroft
Analyst, Jefferies

-reporting the CHIM adult challenge study met its primary endpoint, and the infant study showed significant anti-LPS IgG increases across the four serotypes. Versus your expectations, how robust was protection against shigellosis, and did the challenge data define an anti-LPS IgG threshold associated with protection, and what proportion of infants reached that level?

Thomas Lingelbach
CEO, Valneva

Yeah. So, you raised a couple of questions in one sentence, so let me try to be precise here. We got quite excited about the Shigella data. The Shigella program is a program that we in-licensed from LimmaTech. We have been thinking about going into the enteric disease field more broadly post-Lyme success. We saw for the very first time, A, that the controlled human infection model worked, so the challenge model itself worked very, very nicely. We also saw a very clear level of immunogenicity that correlated with efficacy. We will not educate the world about that threshold, but we saw it, which is pretty exciting because it helps you de-risking a program early on. What we also contemplated during our release around the data was that the study also showed that further optimization is needed to make the response more consistent across the entire population.

We saw some in the study where it worked out pretty well. We saw others where it did not, which clearly shows you that you need to further optimize dose and schedule, which is a work that wasn't done beforehand. This points you a little bit in the direction of what we're going to do next, right? Of course, it is fair to say that Valneva right now has slowed down its investments or its progression on the pipeline. We have put ourselves a little bit into cash containment until we're going to have certainty and more certainty on Lyme. Hopefully, the market reappreciates the value of Lyme, and then we will go full steam ahead on the next development steps, both in adults as well as in children.

Maury Raycroft
Analyst, Jefferies

Got it. So for optimization steps, those are basically on hold until

Thomas Lingelbach
CEO, Valneva

We work, of course, in planning those studies right now, but we will not kick off the studies until we have further clarity on Lyme disease, because we have to be careful that the cash we have in hand will be sufficient until we have the ability to either raise new capital or get milestone payments from Pfizer on the back of Lyme.

Maury Raycroft
Analyst, Jefferies

Got it. Makes sense. Going back to Lyme, you mentioned working hypothesis is that Pfizer would be ready to launch in Europe in the fall of next year. Do you think they would provide more clarity around their commercial plans before then?

Thomas Lingelbach
CEO, Valneva

Personally, I think so, but I cannot talk about Pfizer's commercial behavior here.

Maury Raycroft
Analyst, Jefferies

Yeah.

Thomas Lingelbach
CEO, Valneva

I can only say what Valneva's hypothesis is, and yes, our hypothesis is that they will provide more insights.

Maury Raycroft
Analyst, Jefferies

Right. As far as the opportunity goes, what are your latest thoughts for the Lyme opportunity? You said 50% U.S., 50% ex-U.S.

Thomas Lingelbach
CEO, Valneva

Yeah. I think you have probably noticed that many analysts are working on different Lyme models, different independent marketing analysis, and market analysis have been done around Lyme disease. I would say, Pfizer have publicly stated that they expect annual sales north of $1 billion. When you look at the different analysis that are out there, they range anywhere in between, I would say, $1 billion and $3 billion in terms of market opportunity. This is probably the right order of magnitude that we are thinking about. The fact that the market in Europe will be at least as big as in the United States is simply explained by the number of individuals living in high-risk areas for Lyme disease, more than 200 million people in Europe and 80 million to 90 million in the United States.

Even ignoring things like Favored Nation Act and pricing and whatsoever, you don't need a crystal ball to predict how the market opportunities lie.

Maury Raycroft
Analyst, Jefferies

Got it. I think we're out of time. Maybe in closing, if you want to say anything on commercial, which we didn't talk a whole lot about, and just key catalysts ahead.

Thomas Lingelbach
CEO, Valneva

Yeah, look, first of all, as I said, we have a solid commercial business in travel vaccines. It is cash generative. It represents the base, the floor of our business. We are anticipating a new contract for our Japanese encephalitis vaccine with the Department of Defense coming up very soon, which is important for the company because it provides this financial foundation, especially since the commercial business is cash generative. Upcoming catalysts, certainly the DoD contract is a material one coming up, and then, of course, the next steps on Lyme disease, and hopefully then the progression of Shigella to the next development stage at the latter part of next year. But also, not to be neglected, the company has excellent assets that are awaiting clinical entry, where we slowed down clinical entry, EBV.

We believe we have a highly differentiated asset in the field of EBV, and we believe that on the back of Shigella and probably more, we could also think more broadly about enteric combination vaccines.

Maury Raycroft
Analyst, Jefferies

Makes sense. Thank you very much for joining us today, Thomas.

Thomas Lingelbach
CEO, Valneva

Thank you, Maury.